UpcomingPDUFA target action date

Yeztugo (lenacapavir) 300 mg once-weekly oral

Gilead Sciences (GILD)

Marketer take

Would add a weekly oral option to an existing PrEP brand, giving HIV prevention marketers a new dosing-choice message.

Sponsor company
Gilead Sciences (GILD)
Indication
HIV pre-exposure prophylaxis (sNDA)
Therapeutic area
Infectious disease
Event
PDUFA target action date
Date
Feb 2, 2027
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move